Clinical trials: Recurrent Langerhans Cell Histiocytosis
Langerhans Cell Histiocytosis, LCH
To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
This is a rare disease, single-arm, open-label,multi-center, non-randomized Phase 2 clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of FCN-159 monotherapy in pediatric patients with…
- Trial name
- NCT05997602
- Testing
- FCN-159
- Where
- 11 sites in China
- Volunteers
- 56 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.